Last reviewed 2026-04-19 · How we verify

SULOPENEM

12.1 Mechanism of Action ORLYNVAH is a combination of sulopenem etzadroxil, a penem antibacterial drug [see Microbiology 12.4 ] and probenecid, a renal tubular transport inhibitor.

At a glance

Mechanism of action

12.1 Mechanism of Action ORLYNVAH is a combination of sulopenem etzadroxil, a penem antibacterial drug [see Microbiology 12.4 ] and probenecid, a renal tubular transport inhibitor. Probenecid inhibits OAT3-mediated renal clearance of sulopenem, resulting in increased plasma concentrations of sulopenem .

Approved indications

No approved indications tracked.

Common side effects

• nts treated with ORLYNVAH were all female
• predominantly White
• and from the United States

Drug interactions

• Ketoprofen
• ) See full prescribing information for additional

Key clinical trials

• Pharmacokinetics of Sulopenem Etzadroxil Plus Probenecid in Adolescents (PHASE1)
• Oral Sulopenem Versus Amoxicillin/Clavulanate for Uncomplicated Urinary Tract Infection in Adult Women (PHASE3)
• Expanded Access Use of Sulopenem Etzadroxil/Probenecid for Complicated Urinary Tract Infection
• Safety, Tolerability, and Pharmacokinetics of Sulopenem in Adolescents (PHASE1)
• Oral Sulopenem-etzadroxil/Probenecid Versus Ciprofloxacin for Uncomplicated Urinary Tract Infection in Adult Women (PHASE3)
• Sulopenem Followed by Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro for Complicated UTI in Adults (PHASE3)
• Sulopenem Versus Ertapenem for Complicated Intra-abdominal Infection (cIAI) (PHASE3)
• A Study To Investigate The Pharmacokinetics, Safety And Tolerability Of An Intravenous And Oral Form Of A Compound In Subjects With Varying Degrees Of Renal Impairment And Normal Renal Function (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.